Bardavon Health Innovations' Series C Funding to Expedite...

Bardavon Health Innovations' Series C Funding to Expedite Go-To-Market Efforts

Healthcare Tech Outlook | Wednesday, November 10, 2021

Bardavon Health Innovations raises $90 Million in series C capital.

FREMONT, CA: “We started this company with an eye toward revolutionizing and disrupting the Workers Compensation industry,” states Matthew Condon, Founder and CEO of Bardavon. “It has been a privilege to raise the standard and quality of healthcare for Americas injured workers while spotlighting the importance of proactive, preventative, and clinically directed network management in the Workers Compensation segment.” Bardavon Health Innovations, a Workers Compensation and musculoskeletal (MSK) health startup, has secured a Series C funding of $90 million headed by investor Matrix Capital Management, a public and private investment organization, joined by WestCap, a growth equity firm.

The funding will be used to expedite go-to-market efforts, develop capabilities, and deliver new offers and services to all-payer classes. Bardavon, a privately held digital health partner in Kansas City, unites all stakeholders to improve MSK injury and health management. Its proactive and prospective approach integrates digital health technologies and specialized therapeutic physical rehabilitation treatments. The company currently employs more than 220 people. “This infusion of capital allows us to take the next step to bring meaningful change to an increasingly burdened healthcare system. Its time to expand and share our collaborative solution beyond Workers Compensation especially as our population ages, obesity increases, and national spending on MSK-related injuries skyrockets.” concludes Matthew.

“There is a great opportunity to be had with MSK health,” comments Karan Takhar, Senior Managing Director at Matrix Capital Management. “Our research shows that America’s largest employers are desperate for a viable MSK health, wellness, and care solution. Bardavon, and their MSK health solutions, upend the current marketplace model. Their solutions bring desperately needed transparency, innovation, and relevant clinical treatment data to positively impact MSK care for all. We look forward to helping them take these solutions to a wider general health population.”

Weekly Brief